Clinical trial
A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Ten-week Prospective Study to Evaluate the Efficacy and Safety of NOE-105 in Adult Male Patients With Childhood Onset Fluency Disorder (Orpheus)
NCT05583955 is registered in ClinicalTrials.gov with Noema Pharma AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Ten-week Prospective Study to Evaluate the Efficacy and Safety of NOE-105 in Adult Male Patients With Childhood Onset Fluency Disorder (Orpheus)
- Lead sponsor
- Noema Pharma AG
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 25, 2022
- Completion date
- November 24, 2023
- Enrollment
- 75 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.